AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events

AI Summary

A study found that monthly pelacarsen treatment lowered lipoprotein(a) levels in adults with preexisting cardiovascular disease but did not reduce major adverse cardiovascular events. The findings were published in the New England Journal of Medicine alongside the 2026 American Heart Association Scientific Sessions in Chicago.

For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9 in Chicago.